Loading
Trevena Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Bourdow Carrie L., was filed 28 Jun 2021.
Trevena Inc: what insiders have been doing
Every trade that managers of Trevena Inc disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in King of Prussia, United States. It was founded in 2007. No insider at Trevena Inc has published a filing in the past twelve months. The most recent one dates from 10 October 2024.
The full history, which starts in 2016, counts 10 purchases against 3 sales.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and EssilorLuxottica. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
144
Thresholds
n/a
Buy Volume
€446,731
10 ops. · all time
Sell Volume
€19,518
3 ops. · all time
Since the insiders bought
- -77.0%Entry US$1,112.50 · Close at T+365 US$256.25
- -67.6%Entry US$3,437.50 · Close at T+365 US$1,112.50
- -67.6%Entry US$3,437.50 · Close at T+365 US$1,112.50
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
US$0.00
Analyst consensus
Income statement
RevenueUS$3.1M
Gross profitUS$1.5M47% margin
EBITDA-US$36M-1152% margin
Net income-US$40.3M-1289.2% margin
Valuation
Beta-1.95
Balance sheet & cash
Total debtUS$36.2M
Free Cash Flow-US$33.1M
Profitability & ownership
ROA-62.4%
% institutions11.0%
Last declaration on 10 October 2024
Declarations144 total
488 shares@ US$1.470.0% of flowCommon StockSEC:0001062993-24-017558:4
1,055 shares@ US$1.470.0% of flowCommon StockSEC:0001062993-24-017557:4
45 shares@ US$1.47Common StockSEC:0001062993-24-017559:1
144 shares@ US$1.47Common StockSEC:0001062993-24-017559:2
532 shares@ US$1.470.0% of flowCommon StockSEC:0001062993-24-017559:4
41 shares@ US$1.47Common StockSEC:0001062993-24-017558:1
130 shares@ US$1.47Common StockSEC:0001062993-24-017558:2
143 shares@ US$1.47Common StockSEC:0001062993-24-017557:1
285 shares@ US$1.47Common StockSEC:0001062993-24-017557:2
17 shares@ US$1.470.4% of flowCommon StockSEC:0001062993-24-017558:0
20 shares@ US$1.470.2% of flowCommon StockSEC:0001062993-24-017559:0
54 shares@ US$1.472.6% of flowCommon StockSEC:0001062993-24-017557:0
3 shares@ US$5.950.3% of flowCommon StockSEC:0001062993-24-016705:0
487 shares@ US$5.9521.9% of flowCommon StockSEC:0001062993-24-016707:0
1,929 shares@ US$0.610.0% of flowCommon StockSEC:0001062993-23-022687:2
1,835 shares@ US$0.610.0% of flowCommon StockSEC:0001062993-23-022691:2
50,000 shares@ US$0.61Common StockSEC:0001062993-23-022689:1
3,616 shares@ US$0.61Common StockSEC:0001062993-23-022689:2
50,000 shares@ US$0.61Common StockSEC:0001062993-23-022688:1
3,593 shares@ US$0.61Common StockSEC:0001062993-23-022688:2
25,000 shares@ US$0.61Common StockSEC:0001062993-23-022687:1
100,000 shares@ US$0.61Common StockSEC:0001062993-23-022690:1
7,123 shares@ US$0.61Common StockSEC:0001062993-23-022690:2
25,000 shares@ US$0.61Common StockSEC:0001062993-23-022691:1
50,000 shares@ €0.560390.3% of flowCommon StockSEC:0001062993-23-022691:0
25 of 144 declarations
About Trevena Inc
Trevena, Inc. is a U.S.-listed biopharmaceutical company trading on the NASDAQ under the ticker TRVN, with headquarters in King of Prussia, Pennsylvania, United States. From an international equity analyst’s perspective, Trevena is a small-cap healthcare name with a distinctly high-risk/high-reward profile. The company has historically focused on discovering and developing novel medicines for central nervous system (CNS) disorders, while more recently narrowing its operational emphasis around a commercial product and a smaller set of development-stage assets.
Trevena was founded in the mid-2000s and built its scientific identity around biased ligand technology targeting G protein-coupled receptors (GPCRs). The original investment case was based on the idea that GPCR signaling could be modulated in a more selective way, potentially improving efficacy and tolerability relative to traditional therapies. Over time, however, the company’s strategy has evolved from broad platform expansion toward capital discipline, selective development, and the preservation of shareholder value through a more concentrated pipeline.
Read moreShow less
Its principal marketed product is OLINVYK® (oliceridine), an FDA-approved injectable opioid analgesic indicated in adults for the management of acute pain severe enough to require an intravenous opioid and for whom alternative treatments are inadequate. In addition to OLINVYK, Trevena has maintained several investigational assets, including TRV045, a novel S1P receptor modulator being explored for conditions such as diabetic neuropathic pain and epilepsy, along with earlier-stage or legacy programs such as TRV250 and TRV734. This makes Trevena a classic development-stage biotech with a commercial element: the equity story depends on regulatory progress, clinical execution, and the company’s ability to extend the life and economic value of a limited asset base.
Competitive positioning remains specialized rather than broad-based. Trevena does not compete on scale with large-cap pharmaceutical companies; instead, its edge lies in scientific differentiation, a targeted CNS franchise, and exposure to therapeutic areas with meaningful unmet medical need, especially pain management and selected neurological indications. As a result, the company’s market position is best understood as that of a niche biotech, where investor outcomes are heavily influenced by clinical data, financing conditions, and any partnering or out-licensing opportunities.
Geographically, Trevena’s operating footprint is primarily centered in the United States, even if future collaborations or commercialization arrangements could involve broader international reach. Recent company updates have highlighted ongoing work on TRV045 and a reduction in commercial support for OLINVYK, underscoring a strategy focused on conserving cash and prioritizing the programs that management believes offer the best long-term value creation potential. For investors, TRVN should be viewed as a catalyst-driven biotech security with elevated volatility, binary development risk, and potential dilution risk typical of the sector.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
